SEC Form 4 · accession 0000891293-17-000004
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce J. Seeley
Officer — EVP, Chief Commercial Officer
Period of report
Dec 31, 2016
Accepted (ET)
Jan 3, 2017 · 7:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 31, 2016 | A | 5,000 | $0.3046 | A | 310,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan. The number of shares purchased was before giving effect to the January 1, 2017 reverse stock split.